Literature DB >> 30041176

Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease Patients with Frequent Hospitalized Exacerbations: A Prospective Multicentre Study.

Ana Rodrigo-Troyano1,2, Valentina Melo3, Pedro J Marcos4, Elena Laserna5, Meritxell Peiro1,2, Guillermo Suarez-Cuartin1,2, Lidia Perea2, Anna Feliu2, Vicente Plaza1,2, Paola Faverio6, Marcos I Restrepo3, Antonio Anzueto3, Oriol Sibila1,2.   

Abstract

BACKGROUND: Pseudomonas aeruginosa (PA) is a common microorganism related to severe exacerbations in Chronic Obstructive Pulmonary Disease (COPD). However, their role in COPD patients with frequent hospitalized exacerbations (FHE) is not well described.
OBJECTIVES: We aimed to determine prevalence, risk factors, susceptibility patterns and impact on outcomes of PA in COPD patients with FHE.
METHODS: Prospective observational multicentre study that included COPD patients with FHE. The cohort was stratified in 2 groups according to the presence or absence of PA isolation in sputum. Patients were followed up for 12 months.
RESULTS: We enrolled 207 COPD patients with FHE. In 119 patients (57%), a valid sputum culture was collected. Of them, PA was isolated in 21 patients (18%). The risk factors associated with PA were prior use of systemic corticosteroids (OR 3.3, 95% CI 1.2-9.7, p = 0.01) and prior isolation of PA (OR 4.36, 95% CI 1.4-13.4, p < 0.01). Patients with PA had an increased risk of having ≥3 readmissions (OR 4.1, 95% CI 1.3-12.8, p = 0.01) and higher PA isolation rate (OR 7.7, 95% CI 2.4-24.6, p < 0.001) during the follow-up period. In 14 patients (67%), PA was resistant to at least one antibiotic tested. PA persisted in the sputum in 70% of patients.
CONCLUSIONS: The presence of PA was related to 3 or more readmissions during the 1-year follow-up and PA persisted in the sputum despite an appropriate antibiotic treatment. This finding suggested an important role of PA in the course of the disease of COPD patients with FHE.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Chronic obstructive pulmonary disease; Exacerbation; Pseudomonas aeruginosa; Readmission; Risk factors

Mesh:

Year:  2018        PMID: 30041176     DOI: 10.1159/000490190

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  6 in total

1.  Extracellular products-mediated interspecific interaction between Pseudomonas aeruginosa and Escherichia coli.

Authors:  Yang Yuan; Jing Li; Jiafu Lin; Wenjuan Pan; Yiwen Chu; Balakrishnan Prithiviraj; Yidong Guo; Xinrong Wang; Kelei Zhao
Journal:  J Microbiol       Date:  2020-12-23       Impact factor: 3.422

2.  Elastase Activity From Pseudomonas aeruginosa Respiratory Isolates and ICU Mortality.

Authors:  Jill Zupetic; Hernán F Peñaloza; William Bain; Mei Hulver; Roberta Mettus; Peter Jorth; Yohei Doi; Jennifer Bomberger; Joseph Pilewski; Mehdi Nouraie; Janet S Lee
Journal:  Chest       Date:  2021-04-17       Impact factor: 9.410

Review 3.  [Current microbiological aspects of community respiratory infection beyond COVID-19].

Authors:  R Cantón
Journal:  Rev Esp Quimioter       Date:  2021-03-22       Impact factor: 1.553

4.  Effectiveness of empirical anti-pseudomonal antibiotics for recurrent COPD exacerbation: a multicenter retrospective cohort study.

Authors:  Akihiro Shiroshita; Chisato Miyakoshi; Shunta Tsutsumi; Hiroshi Shiba; Chigusa Shirakawa; Kenya Sato; Shinya Matsushita; Yuya Kimura; Keisuke Tomii; Masahiro Ohgiya; Yuki Kataoka
Journal:  Sci Rep       Date:  2021-10-08       Impact factor: 4.379

5.  Long-Term Risk of Mortality Associated with Isolation of Pseudomonas aeruginosa in COPD: A Systematic Review and Meta-Analysis.

Authors:  Miguel Angel Martinez-García; David Rigau; Miriam Barrecheguren; Alberto García-Ortega; Alexa Nuñez; Grace Oscullo Yepez; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-02-16

Review 6.  An Organ System-Based Synopsis of Pseudomonas aeruginosa Virulence.

Authors:  Charles D Morin; Eric Déziel; Jeff Gauthier; Roger C Levesque; Gee W Lau
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.